$CVKD SEC Filings

Filed On	Filing
13 Oct 2026	Form 4: Pham Quang X, Director Granted 200,000 Stock Option
13 Oct 2026	Form 4: Golden Lee Scott, Director Granted 75,000 Stock Option
13 Oct 2026	Form 4: Murphy John Raymond, Director Granted 75,000 Stock Option
13 Oct 2026	Form 4: Cole Jeffrey Scott, Chief Operating Officer Granted 150,000 Stock Option
13 Oct 2026	Form 4: Wilson Glynn, Director Granted 75,000 Stock Option
08 Oct 2026	REGISTRATION STATEMENT
07 Oct 2026	8-K: Regulation FD Disclosure; Other Events CADRENAL THERAPEUTICS RETAINS TUNGSTEN ADVISORS TO LEAD FORMAL STRATEGIC PROCESS TO MAXIMIZE VALUE OF ITS ORPHAN THROMBO-INFLAMMATORY THERAPEUTICS
29 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders WHEREAS, the Board of Directors (the “Board”) of Cadrenal Therapeutics, Inc. (the “Company”) heretofore established the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan, as amended (the “Plan”); and
03 Sep 2026	REGISTRATION STATEMENT
31 Aug 2026	8-K: Regulation FD Disclosure; Other Events
13 Aug 2026	8-K: Results of Operations and Financial Condition
13 Aug 2026	QUARTERLY REPORT
07 Aug 2026	SCHEDULE 13G
03 Aug 2026	DEFINITIVE ADDITIONAL MATERIALS
03 Aug 2026	FORM ARS
03 Aug 2026	Proxy statement: annual meeting on September 24, 2026
23 Jul 2026	PROXY STATEMENT
21 Jul 2026	8-K: Regulation FD Disclosure; Other Events
20 Jul 2026	EFFECT
20 Jul 2026	PROSPECTUS

Comments